EVAX
Evaxion AS
NASDAQ · Healthcare · Biotechnology · DK
$3.27
+1.55%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.22
From 52W high−70.30%
Volume42867.00
Market cap$29.50M
P/E (TTM)—
P/S (TTM)3.9x
Div yield—
Key dataSep 18, 2026
Open
$3.22
From 52W high
−70.30%
Volume
42867.00
Market cap
$29.50M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
P/E (TTM)
—
RSI (14)
53.8
MomentumView details →
1D Return
+1.55%
YTD Return
−32.91%
SummaryUpdated Jun 1, 2026
Evaxion Biotech A/S (NASDAQ:EVAX) is a Danish clinical-stage biotechnology company founded in 2008 and headquartered in Hørsholm, Denmark. The company went public on NASDAQ in February 2021. Evaxion specializes in developing artificial intelligence-powered immunotherapies targeting cancers, bacterial diseases, and viral infections. The company has evolved from a traditional biotech firm into an AI-driven immunotherapy platform company, leveraging proprietary machine learning algorithms to identify and develop novel vaccine candidates across multiple therapeutic areas.
Similar companies
Latest newsMore news →